Paracelsian Announces Expanded Sales Program
ITHACA, N.Y., Jan. 18 /PRNewswire/ -- Paracelsian, Inc.
(OTC Bulletin Board: PRLN - news) Ithaca, N.Y., announced today that Ernest A. Knesel has agreed to join Paracelsian's Ah Immunoassay Sales and Marketing team.
Mr. Knesel will lead the efforts of this team to implement an aggressive strategy for generating additional revenue from Paracelsian's Ah Immunoassay -- a bioassay for the detection and measurement of dioxin in the environment.
Mr. Knesel brings with him a long history of entrepreneurial involvement.
Mr. Knesel is best known as a founder of Biomedical Reference Laboratories, Inc. and Roche Biomedical Laboratories, Inc.
Roche Biomedical Laboratories was the predecessor company to Laboratory Corporation of America (Ticker Symbol ``LH''), the second largest clinical laboratory in the world. In 1992, Mr. Knesel founded Roche Image Analysis Systems, which later became AutoCyte, Inc.
Most recently, Mr. Knesel was employed as a senior executive in TriPath Imaging, Inc.
Mr. Knesel joins Noriyoshi Inoue and Andrew Jolin on the sales and marketing team. Mr. Inoue and Mr. Jolin have been largely responsible for Paracelsian's expanding relationship with Kubota Corporation of Japan and for additional sales leads. Also participating in this expanded sales and marketing effort is J. Ronald Hass, CEO and President of Triangle Laboratories.
As recently announced, Triangle Laboratories and Paracelsian have entered into a strategic partnership.
Led by Mr. Hass, Triangle Laboratories has agreed to collaborate with Paracelsian in the development of a presentation that joins Paracelsian's Ah Immunoassay with the high resolution gas chromatography/high resolution mass spectrometry (HRGC/HRMS) testing capability of Triangle.
The parties then expect to deliver this presentation to existing customers of Triangle. ``Over the past 12 months, we have made important strides in the development of our Ah Immunoassay and in the development of our relationship with Kubota Corporation,'' said Dr. Colin Campbell, President and CEO of Paracelsian.
``Now that we have developed the Ah Immunoassay into a marketable product that has been validated by a credible corporate partner (Kubota), we are well positioned for an aggressive international rollout of this product,'' continued Dr. Campbell.
``Assembling a team of highly accomplished individuals as we have done is the first step in that rollout,'' continued Dr. Campbell.
``We are pleased that Mr. Knesel has agreed to provide the day-to-day coordination that will be necessary to ensure that our efforts are focused and ultimately effective,'' concluded Dr. Campbell.
``After careful consideration and assessment of Paracelsian's technology, I am encouraged by both the broad application potential and the opportunity for significant market acceptance,'' said Ernest Knesel.
``I eagerly join the Paracelsian team committed to maximizing the success of this unique product,'' concluded Mr. Knesel.
Paracelsian is a unique biotechnology company with three primary areas of focus. Paracelsian develops technologies useful in the detection and monitoring of environmental contaminants such as dioxin.
Second, Paracelsian develops functional bioassays, which are the basis of its BioFIT(TM) Quality Assurance program for herbs, botanicals and other dietary supplements.
And finally, Paracelsian's Internet business leverages extensive relationships in China, along with expertise in nutritional science, to provide an exchange of unique health products and research services.
Notice: This news release may contain forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
SOURCE:Paracelsian, Inc.
Freedom |
